Anti-gout drugs are coming together, and the market for over 3 billion is about to start!

Gout is a kind of hyperuricemia, which is defined internationally as the fasting blood uric acid level on two different days under a normal purine diet
.
Male blood uric acid>420 micromole per liter, female blood uric acid>360 micromole per liter
.
At present, with the improvement of people's living standards, the number of gout patients has begun to increase, and it is gradually showing a "younger" trend
.
At the same time, with the increase in the incidence of gout, China's anti-gout drug market is gradually rising
.
According to data, in recent years, the market for terminal anti-gout preparations in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has expanded year by year.
It has exceeded 2 billion yuan in 2019, and in 2020 It has exceeded 3 billion yuan, an increase of 8.
6% year-on-year
.
It is understood that most gout patients need life-long uric acid-lowering drug treatment, so this has also driven the continued development of the anti-gout drug market
.
At present, in the face of the huge anti-gout drug market, major domestic pharmaceutical companies are deploying one after another, including the development of new anti-gout drugs through independent research and development or introduction
.
In this context, research and development results of related drugs have also begun to emerge
.
For example, a few days ago, the clinical application of Tonghua Dongbao's new class 1 anti-gout drug THDBH130 tablets was accepted by CDE
.
It is reported that this drug is an imported product
.
On June 30, Tonghua Dongbao announced that its subsidiary Dongbao Zixing and WuXi AppTec signed a technology transfer contract and obtained THDB130/THDB131 and THDB150/THDB151 two anti-gout (hyperuricemia) class 1 new drugs in the world The ownership of intellectual property rights within the scope and the benefits related to it
.
On September 9, Hengrui Medicine also announced that the 20mg febuxostat tablets received a drug registration certificate approved and issued by the State Food and Drug Administration
.
It is reported that febuxostat is a xanthine oxidase inhibitor that reduces serum uric acid concentration by inhibiting uric acid synthesis and is suitable for long-term treatment of hyperuricemia in patients with gout
.
Public information shows that febuxostat tablets were originally developed by Japan's Teijin Pharmaceuticals and were approved for listing in the United States in 2009.
They are now widely available in many countries and regions, including China
.
Incomplete statistics show that there are more than 30 new anti-gout drugs from Hengrui, Chengdu Haichuang, Yingli Pharmaceutical, Jiaochen Biological, Kangyuan Pharmaceutical and other companies are also in the clinical and above stage of approval, of which 23 The model is a class 1 new drug
.
In terms of drug types, there are 18, 8 and 10 chemical drugs, therapeutic biological products, and Chinese patent medicines
.
It can be seen from the above that in recent years, more and more domestic companies are developing new anti-gout drugs through independent research and development or introduction
.
The industry believes that under the background that Chinese patients with hyperuricemia and gout still have an urgent need for high-efficiency and safe uric acid-lowering drugs, Hengrui, Chengdu Haichuang Pharmaceutical, Yingli Pharmaceutical, and Simcere will be deployed in the research and development of new anti-gout drugs.
Pharmaceuticals, Changchun Jinsai and other companies will provide patients with more and better choices
.
But at the same time, with the continuous emergence of research and development results of major pharmaceutical companies and successive listings, the market competition for large varieties of anti-gout drugs will become more intense in the future
.